Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype
Cristina Pellegrini(University of L'Aquila), Maria Concetta Fargnoli(University of L'Aquila), Pietro Leocata(University of L'Aquila), Gianluca Cipolloni(San Salvatore Hospital), Ambra Antonini(University of L'Aquila), Lucia Di Nardo(Università Cattolica del Sacro Cuore), Marina De Padova(University of L'Aquila), Maria Giovanna Maturo(University of L'Aquila), Tamara Micantonio(University of L'Aquila), Ketty Peris(Agostino Gemelli University Polyclinic), Laura Del Regno(Agostino Gemelli University Polyclinic), Claudia Martorelli(University of L'Aquila), Sara Strafella(University of L'Aquila)
Cited by 25
Related Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
|European Journal of Cancer|2020|324
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
|European Journal of Cancer|2022|320